VOR Latest Press Releases

-- November 13, 2025 --

Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update Globe Newswire 4:01 PM

-- November 10, 2025 --

Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock Globe Newswire 9:56 PM

Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock Globe Newswire 4:01 PM

-- November 8, 2025 --

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China Globe Newswire 11:45 AM

-- November 7, 2025 --

Vor Bio to Participate in Upcoming Investor Conferences Globe Newswire 8:00 AM

-- November 3, 2025 --

Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer Globe Newswire 8:00 AM

-- October 31, 2025 --

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- October 29, 2025 --

Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data Globe Newswire 11:01 AM

-- October 22, 2025 --

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjgren's Disease Globe Newswire 4:30 PM

-- October 17, 2025 --

Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology's Kidney Week 2025 Globe Newswire 8:00 AM

-- October 16, 2025 --

Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine Globe Newswire 8:00 AM

-- October 14, 2025 --

Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjgren's Disease at ACR 2025 Globe Newswire 8:00 AM

-- October 3, 2025 --

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- September 29, 2025 --

Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjgren's Disease Clinical Study at ACR Convergence 2025 Globe Newswire 7:00 AM

-- September 23, 2025 --

Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer Globe Newswire 8:00 AM

-- September 17, 2025 --

Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting PRNewswire 9:00 PM

Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM Globe Newswire 4:15 PM

-- September 12, 2025 --

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum Globe Newswire 4:15 PM

-- September 2, 2025 --

Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel Globe Newswire 8:00 AM

-- August 28, 2025 --

PureTech Health plc - Half-Year Report Business Wire 2:00 AM

-- August 27, 2025 --

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy Globe Newswire 8:00 AM

-- August 26, 2025 --

Vor Bio to Participate in Upcoming Investor Conferences Globe Newswire 8:00 AM

-- August 18, 2025 --

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:35 PM

-- August 13, 2025 --

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjgren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor Globe Newswire 8:30 AM

-- August 4, 2025 --

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer Globe Newswire 8:30 AM

-- July 21, 2025 --

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors Globe Newswire 8:30 AM

-- July 18, 2025 --

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM

-- July 17, 2025 --

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer Globe Newswire 8:30 AM